ALB and neoplasm: The following data were similar between the two groups: median ICT duration (3 months [2.7–4.5] vs 4.2 months [2.1–5.7]; p = 0.55), total duration of induction treatment including CRT (6.2 months [5.3–8.1] vs 6 months [5.6–8.7]; p = 0.63), median level of bilirubin (6 μmol/L [5–9] and 6 μmol/L [4.5–8.8]; p = 0.78), albumin (34.5 g/L [33.1–35.8] vs 36.3 g/L [33.8–40]; p = 0.67), CA19.9 levels (108.7UI/L [36.8–494.2] vs 57UI/L [24.1–224.6]; p = 0.85), CA19.9 variation from baseline (−165.5 [−278.8–−65.9] vs −3.4 [−257–+20.4]; p = 0.15), and tumor response rate (18.8% vs 20.0%; p = 1.0).